Neuren Pharmaceuticals Ltd
ASX:NEU
Neuren Pharmaceuticals Ltd
Common Stock
Neuren Pharmaceuticals Ltd
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Common Stock
AU$165.3m
|
CAGR 3-Years
0%
|
CAGR 5-Years
6%
|
CAGR 10-Years
5%
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Common Stock
AU$1.2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Common Stock
AU$188.8m
|
CAGR 3-Years
38%
|
CAGR 5-Years
21%
|
CAGR 10-Years
22%
|
|
|
Probiotec Ltd
ASX:PBP
|
Common Stock
AU$53.2m
|
CAGR 3-Years
2%
|
CAGR 5-Years
8%
|
CAGR 10-Years
5%
|
|
|
Argenica Therapeutics Ltd
ASX:AGN
|
Common Stock
AU$28.4m
|
CAGR 3-Years
52%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Common Stock
AU$45m
|
CAGR 3-Years
3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
0%
|
|
Neuren Pharmaceuticals Ltd
Glance View
Founded in 1993, Neuren Pharmaceuticals Ltd has carved a niche for itself within the biotech industry, focusing primarily on neurological and neurodevelopmental disorders. The company operates at the intriguing intersection of innovation and medicine, where the stakes are high, but so are the potential rewards. Neuren has its headquarters in Australia and has oriented its research towards developing therapies that could change the lives of those affected by conditions like Rett syndrome and Fragile X syndrome. By adopting a strategic approach that combines cutting-edge science with a relentless focus on unmet needs, Neuren positions itself uniquely through its proprietary compounds such as trofinetide and NNZ-2591, which are at the core of its research endeavors. The company's business model hinges on a dual approach: developing its own drugs while simultaneously fostering partnerships with larger pharmaceutical companies to bring these therapies to market. This model allows Neuren to share the substantial costs and risks inherent in drug development while benefiting from the expanse of its partners' distribution networks and market insights. Revenue generation kicks in primarily through milestone payments, royalties, and licensing agreements as these partners help navigate the rigorous phases of clinical trials and regulatory approvals. Financial stability is thus intricately tied to clinical successes and strategic alliances, allowing Neuren to balance the speculative nature of biotech investments with the promise of transformative medical breakthroughs.
See Also
What is Neuren Pharmaceuticals Ltd's Common Stock?
Common Stock
165.3m
AUD
Based on the financial report for Dec 31, 2024, Neuren Pharmaceuticals Ltd's Common Stock amounts to 165.3m AUD.
What is Neuren Pharmaceuticals Ltd's Common Stock growth rate?
Common Stock CAGR 10Y
5%
Over the last year, the Common Stock growth was -5%.
You don't have any saved screeners yet